2023 年，中轴型脊柱关节炎是否需要逐渐减少生物靶向改善病情抗风湿药物：这是一个问题。
To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question.
机构信息
Department of Internal Medicine and Pediatrics, Ghent University, Ghent University Hospital, Ghent, Belgium; VIB Center for Inflammation Research, Ghent, Belgium.
Department of Internal Medicine and Pediatrics, Ghent University, Ghent University Hospital, Ghent, Belgium; VIB Center for Inflammation Research, Ghent, Belgium.
出版信息
Best Pract Res Clin Rheumatol. 2023 Sep;37(3):101869. doi: 10.1016/j.berh.2023.101869. Epub 2023 Aug 30.
The 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) propose to consider dose reduction of biological disease-modifying antirheumatic drugs (bDMARDs) for patients in sustained remission. However, this recommendation does not offer clear guidance for daily clinical practice. In this review, we analyze randomized clinical trials and real-world data on tapering and discontinuation of bDMARDs in patients with axSpA. We discuss the scientific rationale and benefits of tapering, identify advice to apply tapering in current practice, and delineate aspects to be investigated in future research.
2022 年 ASAS-EULAR 推荐意见建议对于持续缓解的轴性脊柱关节炎（axSpA）患者考虑减少生物制剂的剂量。然而，该推荐意见并未为日常临床实践提供明确的指导。在本综述中，我们分析了 axSpA 患者中关于生物制剂减量和停药的随机临床试验和真实世界数据。我们讨论了减量的科学依据和获益，确定了在当前实践中应用减量的建议，并描绘了未来研究需要探讨的方面。
Zotero 插件